Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 13350.0
(0.07%)
KRW 13350.0
(0.07%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 254.23 Billion KRW | 6.85% |
| 2022 | 237.94 Billion KRW | 34.84% |
| 2021 | 176.46 Billion KRW | 6.35% |
| 2020 | 165.93 Billion KRW | -7.89% |
| 2019 | 180.15 Billion KRW | 8.86% |
| 2018 | 165.48 Billion KRW | 8.84% |
| 2017 | 152.04 Billion KRW | 10.57% |
| 2016 | 137.51 Billion KRW | 17.38% |
| 2015 | 117.15 Billion KRW | 16.8% |
| 2014 | 100.3 Billion KRW | 17.98% |
| 2013 | 85.01 Billion KRW | 17.19% |
| 2012 | 72.54 Billion KRW | -6.06% |
| 2011 | 77.22 Billion KRW | -10.58% |
| 2010 | 86.35 Billion KRW | 20.8% |
| 2009 | 71.49 Billion KRW | 19.53% |
| 2008 | 59.81 Billion KRW | 19.2% |
| 2007 | 50.17 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 79.53 Billion KRW | 14.59% |
| 2024 Q2 | 61.52 Billion KRW | -20.32% |
| 2023 Q3 | 60 Billion KRW | -8.38% |
| 2023 Q2 | 65.49 Billion KRW | 7.1% |
| 2023 Q1 | 61.15 Billion KRW | 0.0% |
| 2023 FY | 254.23 Billion KRW | 6.85% |
| 2023 Q4 | 69.41 Billion KRW | 15.67% |
| 2022 Q1 | 57.98 Billion KRW | 17.47% |
| 2022 FY | 237.94 Billion KRW | 34.84% |
| 2022 Q2 | 57.95 Billion KRW | -0.04% |
| 2022 Q3 | 60.84 Billion KRW | 4.99% |
| 2022 Q4 | 61.15 Billion KRW | 0.51% |
| 2021 FY | 176.46 Billion KRW | 6.35% |
| 2021 Q1 | 38.69 Billion KRW | -6.86% |
| 2021 Q2 | 44.83 Billion KRW | 15.88% |
| 2021 Q4 | 49.35 Billion KRW | 13.24% |
| 2021 Q3 | 43.58 Billion KRW | -2.79% |
| 2020 Q1 | 44.77 Billion KRW | -10.18% |
| 2020 Q4 | 41.53 Billion KRW | 3.83% |
| 2020 Q3 | 40 Billion KRW | 0.98% |
| 2020 FY | 165.93 Billion KRW | -7.89% |
| 2020 Q2 | 39.61 Billion KRW | -11.52% |
| 2019 Q3 | 42.76 Billion KRW | -2.96% |
| 2019 FY | 180.15 Billion KRW | 8.86% |
| 2019 Q2 | 44.07 Billion KRW | 1.38% |
| 2019 Q4 | 49.84 Billion KRW | 16.57% |
| 2019 Q1 | 43.47 Billion KRW | -1.81% |
| 2018 Q3 | 37.97 Billion KRW | -8.07% |
| 2018 FY | 165.48 Billion KRW | 8.84% |
| 2018 Q1 | 41.93 Billion KRW | 3.18% |
| 2018 Q4 | 44.27 Billion KRW | 16.59% |
| 2018 Q2 | 41.3 Billion KRW | -1.5% |
| 2017 Q1 | 34.39 Billion KRW | -11.55% |
| 2017 Q4 | 40.64 Billion KRW | 3.98% |
| 2017 FY | 152.04 Billion KRW | 10.57% |
| 2017 Q3 | 39.08 Billion KRW | 3.08% |
| 2017 Q2 | 37.91 Billion KRW | 10.24% |
| 2016 FY | 137.51 Billion KRW | 17.38% |
| 2016 Q2 | 34.15 Billion KRW | 8.91% |
| 2016 Q1 | 31.35 Billion KRW | -5.28% |
| 2016 Q3 | 33.11 Billion KRW | -3.02% |
| 2016 Q4 | 38.88 Billion KRW | 17.42% |
| 2015 FY | 117.15 Billion KRW | 16.8% |
| 2015 Q1 | 27.85 Billion KRW | -0.84% |
| 2015 Q4 | 33.1 Billion KRW | 20.15% |
| 2015 Q3 | 27.55 Billion KRW | -3.79% |
| 2015 Q2 | 28.63 Billion KRW | 2.83% |
| 2014 Q2 | 24.06 Billion KRW | 3.69% |
| 2014 Q1 | 23.2 Billion KRW | -0.6% |
| 2014 FY | 100.3 Billion KRW | 17.98% |
| 2014 Q4 | 28.08 Billion KRW | 12.61% |
| 2014 Q3 | 24.94 Billion KRW | 3.65% |
| 2013 Q2 | 20.84 Billion KRW | 3.98% |
| 2013 Q3 | 20.78 Billion KRW | -0.28% |
| 2013 Q4 | 23.34 Billion KRW | 12.34% |
| 2013 FY | 85.01 Billion KRW | 17.19% |
| 2013 Q1 | 20.04 Billion KRW | -0.28% |
| 2012 Q3 | 17.06 Billion KRW | -4.57% |
| 2012 Q4 | 20.09 Billion KRW | 17.79% |
| 2012 FY | 72.54 Billion KRW | -6.06% |
| 2012 Q1 | 16.8 Billion KRW | 0.0% |
| 2012 Q2 | 17.88 Billion KRW | 6.43% |
| 2011 Q1 | 20 Billion KRW | -7.5% |
| 2011 Q2 | 20.56 Billion KRW | 2.79% |
| 2011 Q3 | 17.43 Billion KRW | -15.22% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 77.22 Billion KRW | -10.58% |
| 2010 Q2 | 22.88 Billion KRW | 9.3% |
| 2010 Q1 | 20.94 Billion KRW | 5.07% |
| 2010 FY | 86.35 Billion KRW | 20.8% |
| 2010 Q3 | 20.89 Billion KRW | -8.69% |
| 2010 Q4 | 21.63 Billion KRW | 3.5% |
| 2009 Q4 | 19.93 Billion KRW | 6.47% |
| 2009 FY | 71.49 Billion KRW | 19.53% |
| 2009 Q3 | 18.71 Billion KRW | 7.35% |
| 2009 Q2 | 17.43 Billion KRW | 13.2% |
| 2009 Q1 | 15.4 Billion KRW | -1.65% |
| 2008 Q3 | 15.23 Billion KRW | 2.75% |
| 2008 Q2 | 14.83 Billion KRW | 5.34% |
| 2008 Q1 | 14.07 Billion KRW | 1.3% |
| 2008 FY | 59.81 Billion KRW | 19.2% |
| 2008 Q4 | 15.66 Billion KRW | 2.78% |
| 2007 FY | 50.17 Billion KRW | 0.0% |
| 2007 Q4 | 13.89 Billion KRW | 17.31% |
| 2007 Q3 | 11.84 Billion KRW | -7.23% |
| 2007 Q2 | 12.77 Billion KRW | 9.52% |
| 2007 Q1 | 11.66 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -38.076% |
| Yuhan Corporation | 564.5 Billion KRW | 54.964% |
| Yuhan Corporation | 564.5 Billion KRW | 54.964% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -446.676% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -446.676% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -446.676% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -27.827% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -252.066% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 30.177% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 24.262% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 24.262% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 24.262% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -970.583% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 31.566% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -525.423% |
| HANDOK Inc. | 151.36 Billion KRW | -67.958% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | -25.969% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -278.183% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -408.002% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 2210.578% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -632.324% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -258.381% |
| Boryung Corporation | 333.26 Billion KRW | 23.716% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -237.904% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -74.261% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -27.779% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -27.779% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -156.73% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 13.854% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -238.797% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -159.089% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -168.985% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -223.369% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -223.369% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -46.542% |
| CKD Bio Corp. | 5.01 Billion KRW | -4974.185% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 62.698% |
| JW Holdings Corporation | 446.15 Billion KRW | 43.017% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -230.952% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 69.584% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 21.098% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 61.206% |
| JW Lifescience Corporation | 51.32 Billion KRW | -395.338% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | -22.499% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -38.309% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -80.491% |